Pharmacy is the new battleground: how to read your Rx spend
Pharmacy is now one of the fastest-growing lines in your benefits budget — and the one almost no employer knows how to read. Here's how to start.
Kyle Kube
Founder, The Benefits CEO · May 13, 2026
Ask most employers what's driving their benefits cost and they'll point to medical claims — hospital stays, surgeries, the big-ticket events. They're increasingly wrong. A growing share of total plan spend now runs through the pharmacy, and it's climbing faster than almost anything else on the medical side. Pharmacy has quietly become the battleground, and most employers show up to it unarmed.
The problem isn't only the cost. It's the visibility. The pharmacy supply chain is deliberately opaque, and the reports employers receive are built to be skimmed, not understood. Here's how to actually read your Rx spend — and what to do once you can.
Why pharmacy is growing so fast
Two forces are doing most of the work. The first is specialty drugs — high-cost medications for complex conditions that are used by a very small share of members but can consume a large share of the pharmacy budget. A single specialty member can cost more than dozens of ordinary ones.
The second is the GLP-1 wave — the class of drugs used for diabetes and, increasingly, weight management. Demand has surged, the price per member is significant, and the population eligible to ask for them is large. Together, specialty and GLP-1s have turned pharmacy from a predictable line item into the most dynamic part of the plan.
A small number of members now drive a large share of pharmacy cost. If you can't see who and what, you can't manage either.
The metrics that actually matter
When you get a pharmacy report, most of it is noise. These are the numbers to find first:
- Pharmacy PMPM (per member per month). Your total Rx spend divided by members and months. This is your headline trend line — track it over time, not just in isolation.
- Specialty as a share of total spend. Specialty is often a low-single-digit share of prescriptions but a very large share of dollars. The gap between those two numbers tells you where the pressure is.
- Generic dispensing rate (GDR). The percentage of prescriptions filled as generics. A high GDR is one of the clearest signs the plan is steering toward lower-cost equivalents; a low one is money left on the table.
- Top therapeutic classes. Which categories of drugs drive your spend — and how much of it is GLP-1s. This is where strategy decisions actually get made.
- Rebates — and where they go. Manufacturer rebates can be substantial. The question is how much of that money flows back to your plan versus staying with the intermediary.
The PBM transparency problem
Your pharmacy benefit is run by a PBM (pharmacy benefit manager), and traditional PBM contracts can make money in ways you never see — spread pricing, retained rebates, and opaque definitions of "generic" and "specialty." The single highest-leverage move many employers can make is moving to a transparent, pass-through PBM arrangement where pricing and rebates are fully disclosed. You can't negotiate what you can't see.
The levers worth pulling
- Audit your PBM contract. Understand how it's actually priced, what counts as what, and where rebate dollars land. Ambiguous definitions are where margin hides.
- Consider a transparent or pass-through PBM. Disclosure aligns incentives and often surfaces savings the incumbent had no reason to mention.
- Manage specialty deliberately. Specialty management programs, site-of-care steering, and manufacturer assistance can meaningfully reduce the cost of your highest-dollar members.
- Set a clear GLP-1 posture. Decide coverage criteria intentionally — with clinical guardrails and engagement programs — rather than letting demand set your policy by default.
- Carve out pharmacy where it makes sense. For many self- and level-funded groups, separating pharmacy from the medical carrier unlocks transparency and competition the bundle never offered.
Questions to ask your advisor or PBM
You don't need to be a pharmacist to hold the conversation. Ask these and listen for whether the answers are specific:
- What is our pharmacy PMPM trend, and how does specialty split between scripts and dollars?
- What share of manufacturer rebates flows back to our plan?
- Is our PBM contract spread-priced or pass-through — and can you prove it?
- What is our GLP-1 exposure today, and what's the projected trajectory?
- What specialty management is in place for our highest-cost members?
The bottom line
Pharmacy is no longer a footnote to the medical plan — it's a primary cost center with its own supply chain, its own economics, and its own opacity. The employers who win here aren't the ones with the most clinical expertise; they're the ones who insist on seeing the data and asking specific questions. Start with your PMPM and your specialty split, demand transparency from your PBM, and set your GLP-1 policy on purpose. The battleground is already here. The only question is whether you show up able to read the map.
Key takeaways
- Pharmacy is one of the fastest-growing plan costs, driven by specialty drugs and the GLP-1 wave.
- Start with five metrics: PMPM, specialty share of dollars, generic dispensing rate, top classes, and rebates.
- Traditional PBM contracts hide margin — a transparent, pass-through arrangement is often the biggest lever.
- Set your specialty and GLP-1 strategy deliberately — don't let demand set policy by default.